Real, J, Franch-Nadal, J, Mauricio, D, Vlacho, B, Carrasco, M, Monroy, G, Hernández, M. IMPACT OF RAMADAN ON OVERDIAGNOSIS OF GESTATIONAL DIABETES: MATCHED CASE-CONTROL ANALYSIS BASED ON CLINICAL REGISTRIES. Gaceta Sanitaria. 2025; 39DOI:. PMID:. IF:1.500(Q3/7D).

Estévez-Arias, B, Segarra-Casas, A, Romo, L, Polavarapu, K, O'Heir, E, Singer-Berk, M, O'Leary, M, Nectoux, J, Spinazzi, M, Leturcq, F, Llanso, L, Domínguez, C, Topf, A, Lochmüller, H, Malfatti, E, Nascimento, A, Gallardo, E, González-Quereda, L, Natera-de Benito, D. A recurrent non-coding 3'UTR variant as a hidden second hit in 11 families with CAPN3-related limb girdle muscular dystrophy. NEUROMUSCULAR DISORDERS. 2025; 53DOI:10.1016/j.nmd.2025.105786. PMID:. IF:2.800(Q2/5D).

Corcoy, R, Mendoza, LC, Serrano, AC, Bonet, M, Mart nez, A, Romero, M, Safont, E, Pujol, I, Lopez, A. International Diabetes Federation 2024 criteria: impact on the postpartum glucose tolerance assessment of women with gestational diabetes. DIABETOLOGIA. 2025; 68DOI:. PMID:. IF:10.200(Q1/1D).

Mesa, A, Puig-Jov , C, Pan , A, Vinagre, I, L pez-Quesada, E, Meler, E, Alonso-Carril, N, Quir s, C, Amor, A, Perea, V. Pre-eclampsia is an independent predictor of atherosclerosis progression in women with type 1 diabetes: a 5 year prospective study. DIABETOLOGIA. 2025; 68DOI:. PMID:. IF:10.200(Q1/1D).

Vi als, C, Conget, I, Granados, M, Sol , C, Mesa, A, Ser s-Noriega, T, Perea, V, Blanco, J, Vinagre, I, Gim nez, M, Amor, A. Impact of cardiovascular risk factors control on atherosclerosis progression in individuals with type 1 diabetes. DIABETOLOGIA. 2025; 68DOI:. PMID:. IF:10.200(Q1/1D).

Macaya, I, Ollé, L, Sánchez, E, Pérez, M, Borrell, C, Pérez, K. THE HOME CARE SERVICE IN BARCELONA AS A MODEL FOR COMMUNITY-BASED CARE SERVICES: A QUALITATIVE APPROACH. Gaceta Sanitaria. 2025; 39DOI:. PMID:. IF:1.500(Q3/7D).

Moreno, BR, Benitez, ID, Erro, M, Burgos, J, Sayés, A, Garcia-Urrestarazu, EJ, Pou, C, Castan, RA, Navarro, A, Fuentes, AMD, Lakhani, JS, Juez-Garcia, I, Manzano, C, Santisteve, S, Morales, A, Monge, A, Moncusi-Moix, A, Sánchez-Cucó, A, Alcaide, AB, de-Torres, JP, Barbé, F, Suarez-Cuartin, G, de la Rosa, D, González, J. Phenotype Analysis of Chronic Bronchial Infection Patients on Inhaled Antibiotic Therapy: A Multicentre Retrospective Cohort Study in Spain (INBREATHING Study). ARCHIVOS DE BRONCONEUMOLOGIA. 2025; 61(9)DOI:10.1016/j.arbres.2025.04.008. PMID:40350352. IF:9.200(Q1/1D).

Franquet, T, Brenes, JM, Radike, M, Giménez, A, Domingo, P. Imaging of Immunodeficiency-Associated Lymphoproliferative Disorders. SEMINARS IN ULTRASOUND CT AND MRI. 2025; 46(4)DOI:10.1053/j.sult.2025.06.001. PMID:40543829. IF:1.900(Q3/6D).

Modest, DP, Fakih, M, Salvatore, L, Esaki, T, Lopez-Bravo, DP, Taieb, J, Karamouzis, M, Ruiz-Garcia, E, Kim, TW, Kuboki, Y, Meriggi, F, Cunningham, D, Yeh, KH, Cremolini, C, Tran, Q, Chan, E, Chao, JS, Majer, IM, Pietrantonio, F. Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial. LANCET ONCOLOGY. 2025; 26(9)DOI:10.1016/S1470-2045(25)00352-3. PMID:40812325. IF:35.900(Q1/1D).

Herrera, IC, Fabregó, IE, Cols, LC, Lladó, MC, Vidal, AG, Martín, LF, Mariscal, IE, Arango, SMR, Metrallé, SCS, Alcañiz, AG. Prognostic significance of genetic biomarkers in glioblastoma IDH wild-type: a retrospective survival analysis. VIRCHOWS ARCHIV. 2025; 487DOI:. PMID:. IF:3.100(Q2/3D).

Riedell, PA, Kwon, M, Flinn, IW, Dickinson, MJ, Solano, C, Jaeger, U, Briones, J, Kato, K, Fleming, S, Bachy, E, Rambaldi, A, Shune, LO, Shah, NN, Blaise, D, Frigault, MJ, Ramakrishnan, A, Yang, A, Pearson, D, Zia, A, Segura, E, Masood, A, Barba, P. Rapcabtagene Autoleucel (YTB323) Phase 2 Trial in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Clinical. Clinical Lymphoma Myeloma & Leukemia. 2025; 25DOI:. PMID:. IF:2.700(Q2/4D).

Jabbour, E, Recher, C, O'Nions, J, Aldoss, I, Pierola, A, Allred, A, Alonso-Dominguez, JM, Barreyro, L, Bories, P, Curtis, M, Daskalakis, N, Della Porta, MG, Döhner, H, D'Souza, A, Dugan, JP, Reyner, JE, Exum, M, Fathi, AT, Fedele, PL, Ferrante, L, Gaj, S, Garciaz, S, Garrido, A, Paniagua, SG, Guttke, C, Gyan, E, Hiebert, B, Jentzsch, M, Kantarjian, HM, Konopleva, M, Krönke, J, Kwon, MC, Loefgren, C, Lomas, O, Mancini, V, Mantzaris, I, Martinelli, G, Giles, DM, Murphy, J, Packman, K, Papayannidis, C, Philippar, U, Platzbecker, U, Rangaraju, S, Röllig, C, Salamero, O, Sanga, M, Sauer, T, Searle, E, Tovar, N, Tucker, T, Vallet, N, Vaughan, L, Vega, G, Vyas, P, Wei, A. Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination With Intensive Chemotherapy (IC) in Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) with KMT2Ar or NPM1 Alterations. Clinical Lymphoma Myeloma & Leukemia. 2025; 25DOI:. PMID:. IF:2.700(Q2/4D).

Moreno, AA, Presas-Rodríguez, S, Gonzalez-Garcia, AM, Teniente-Sera, A, Martínez-Cáceres, EM, Querol, L, Martín-Aguilar, L, Meca-Lallana, JE, Dos Santos, CE, Millán, J, López, GV, Orgaz, ATC, Ruiz, VC, Anunciación, BAJ, Hervas, JV, Ruiz, LB, Bravo, GCA, Ramo, C. Monitoring Patients with Relapsing-Remitting Multiple Sclerosis Switching from Intravenous to Subcutaneous Natalizumab every 4 Weeks vs every 6 Weeks. Multiple Sclerosis Journal. 2025; 31(3)DOI:. PMID:. IF:5.000(Q1/2D).

Luce, L, Kocak, G, Alonso-Pérez, J, Straub,, Töpf, A, Díaz-Manera, J. Cracking the code: genotype-phenotype correlation models in sarcoglycanopathies. NEUROMUSCULAR DISORDERS. 2025; 53DOI:. PMID:. IF:2.800(Q2/5D).

Unoje, O, Hussain, Y, Habib, A, Claeys, K, Gwathmey, K, Sahagian, G, Cortés-Vicente, E, Liu, L, Jimenez, R, Patel, M, Masschaele, D, Mantegazza, R, Meisel, A, Seth, A, Attarian, S. Sustained Clinical Efficacy and Long-Term Safety of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of ADAPT NXT. ANNALS OF NEUROLOGY. 2025; 98DOI:. PMID:. IF:7.700(Q1/1D).

Forcadell-Díez, L, Pérez, G, Fernández, A, Puig-Barrachina, V, Subirats, IG, Cortés, E, Moral, PD, Juárez, O. HOW TO PROMOTE HEALTHY AND EQUITABLE RELATIONSHIPS IN FORMAL EDUCATION: THEORETICAL FRAMEWORK AND EDUCATIONAL PROPOSAL. Gaceta Sanitaria. 2025; 39DOI:. PMID:. IF:1.500(Q3/7D).

Bioque, M, Llorca-Bofi, V, MacDowell, KS, Amoretti, S, Mezquida, G, Cuesta, MJ, Diaz-Caneja, CM, Ibáñez, A, Segarra, R, González-Pinto, A, Roldán, A, Sáiz, PA, Mané, A, Lobo, A, Martínez-Pinteño, A, Cano-Escalera, G, Berrocoso, E, Bernardo, M. Impact of Relapse in BDNF Receptors Expression in Patients With a First Episode of Schizophrenia. SCHIZOPHRENIA BULLETIN. 2025; 51(5)DOI:10.1093/schbul/sbaf012. PMID:39977257. IF:4.800(Q1/2D).

March-Yagüe, A, Toledo, D, Díaz, A, Godoy, P, Pérez-Martinez, O, Pericas, C, Sánchez-Migallón, A, Domínguez, A. MPOX IN PEOPLE WITH HIV AND PREP USERS DURING THE 2022 OUTBREAK, SPAIN. Gaceta Sanitaria. 2025; 39DOI:. PMID:. IF:1.500(Q3/7D).

Velasco, AES, Serrano, MC, Barrufet, C, Augè, JM, Torà, I, Puig, T, Milà, MA, Serra, MS, Pust, AB. PERSONALIZATION OF COLORECTAL CANCER SCREENING BASED ON PREVIOUS NEGATIVE TESTS: HOW MANY TESTS SHOULD BE USED?. Gaceta Sanitaria. 2025; 39DOI:. PMID:. IF:1.500(Q3/7D).

Amengual-Moreno, M, Oliveras, L, Marí-Dell'Olmo, M, Sánchez-Ledesma, E, Cano, GS, Font-Ribera, L. SOCIAL DETERMINANTS OF PROXIMITY-BASED SCHOOLING AND ACTIVE SCHOOL MOBILITY IN ADOLESCENTS IN THE CITY OF BARCELONA. Gaceta Sanitaria. 2025; 39DOI:. PMID:. IF:1.500(Q3/7D).